QINLOCK (ripretinib) tablets

QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST). FDA approved ripretinib (brand name QINLOCK) is not (yet) registered or available in India. The access to the drug is provided as per Name Patient Program respecting the regulatory framework as desired by local authorities.

Home | ripretinib tablets

qinlock
QINLOCK (ripretinib) tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

QINLOCK (ripretinib) tablets

Ripretinib, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.

QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.

The most common side effects include alopecia (hair loss), fatigue, nausea, abdominal pain, constipation, myalgia (muscle pain), diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome (a skin reaction in the palms and soles) and vomiting.

Drug (Brand / Generic): QINLOCK® (ripretinib) tablets, for oral use Initial U.S. Approval: 2020
Current Indication: gastrointestinal stromal tumor (GIST)
Approval Date: 2020

Tablets: 50 mg
Deciphera Pharmaceuticals, LLC

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.